Skip redundant pieces
KU Center for Technology Commercialization


Project TitleBRCA1- Based Breast or Ovarian Cancer Prevention Agents and Methods of Use
Track Code08KU009M
Short Description

This invention is aimed at delaying tumor growth in breast and ovarian cancers by increasing BRCA1 protein expression.

TagsCancer - Ovarian Cancer, breast cancer, protein expression
Posted DateSep 3, 2013 12:37 PM


Frank Schoenen
Gerald Lushington
Jeffrey Aube
Roy Jensen
Lisa Harlan-Williams


Matthew Koenig


This invention is aimed at delaying tumor growth in breast and ovarian cancers by increasing BRCA1 protein expression. BRCA1 has also been implicated in prostate and pancreatic cancer, so these agents could also have an effect on these cancers.


Currently, breast cancer is treated by surgery, radiation therapy, chemotherapy, targeted therapy, and hormonal therapy. 


Hormonal therapy is an option for anyone with hormone receptor positive breast cancer. About 60% of breast cancers are hormone receptor positive. However, there are several side effects with hormonal therapy, including uterine cancer and weakening of the bones.


Current targeted therapies only work for HER2 positive breast cancers. However, only 15 to 20% of women with breast cancer have HER2-positive tumors. 


This invention is a selection of agents that target the tumor suppressor gene, BRCA1. BRCA1 is responsible for many breast and ovarian cancers. Increasing BRCA1 protein expression will prevent or delay the onset of breast or ovarian tumors. BRCA1 is mutated in 5-10% of all breast cancers. However, these agents also target the 90% of sporadic breast cancers that have a normal BRCA1 gene whose protein expression is decreased. The prevention agents can be administered through any medically acceptable mode in either a localized or systemic approach.

Why it is better

By targeting the BRCA1 protein expressed, these prevention agents will reach about 90% of breast cancers where BRCA1 is mutated or ‘turned off.’ Furthermore, the agents can be administered via any medically acceptable mode. Localized administration is possible in addition to a more systematic approach. BRCA1-based treatment option has less severe side effects than traditional breast cancer treatments.

Contact Information

Matt Koenig, J.D.
KU Center for Technology Commercialization (785) 864-1774

Intellectual Property

Patent Number Issue Date Type Country of Filing
EP2214664 None Utility Europe
CA 2705812 None Utility Canada
US8362072 None Utility United States

Page last modified: Thursday December 04, 2008  •  Valid XHTML  •  Copyright © 2008 by the University of Kansas